

The invention relates to the novel cycloalcanols inhibiting cholesterol biosynthesis, in particular the inhibitors of the enzyme 2,3-epoxysqualen-lanosterin-cyclase. These substances may be used for the treatment and prevention of lipidemia, hypercholesterinemia and atherosclerosis. The pharmaceutical formulation containing these substances is also disclosed.